Considerations in the rationale, design and methods of the Strategic Timing of AntiRetroviral Treatment (START) study
Research output: Contribution to journal › Journal article › Research
Untreated human immunodeficiency virus (HIV) infection is characterized by progressive depletion of CD4+ T lymphocyte (CD4) count leading to the development of opportunistic diseases (acquired immunodeficiency syndrome (AIDS)), and more recent data suggest that HIV is also associated with an increased risk of serious non-AIDS (SNA) diseases including cardiovascular, renal, and liver diseases and non-AIDS-defining cancers. Although combination antiretroviral treatment (ART) has resulted in a substantial decrease in morbidity and mortality in persons with HIV infection, viral eradication is not feasible with currently available drugs. The optimal time to start ART for asymptomatic HIV infection is controversial and remains one of the key unanswered questions in the clinical management of HIV-infected individuals.
Original language | English |
---|---|
Journal | Clinical trials (London, England) |
Volume | 10 |
Issue number | 1 Suppl |
Pages (from-to) | S5-S36 |
DOIs | |
Publication status | Published - 2013 |
ID: 93929578